Mutations in ERBB2 are found in 4–6% of patients with CRC, and some of these are activating and can co-occur with HER2 amplification; however, unlike amplifications, ERBB2 mutations are not associated with the RAS/BRAF wild-type status [78,79]. The gene discussed is ERBB2; the disease is colorectal carcinoma.